ELREXFIO (elranatamab-bcmm)
ANTINEOPLASTIC - IMMUNOTHERAPY, T-CELL ENGAGER · MULTIPLE MYELOMA
Laboratories Div
Drug class
Antineoplastic - Immunotherapy, T-cell Engager
Antineoplastic T-cell engager immunotherapies are engineered multispecific biologic agents designed to redirect endogenous cytotoxic T cells to destroy malignant cells. Read more about Antineoplastic - Immunotherapy, T-cell Engager
14 drugs in this class 8 manufacturers
Drugs in Antineoplastic - Immunotherapy, T-cell Engager
IMDELLTRA (tarlatamab-dlle)
ANTINEOPLASTIC - IMMUNOTHERAPY, T-CELL ENGAGER · EXTENSIVE-STAGE SMALL CELL LUNG CANCER
AMGEN
ELREXFIO (elranatamab-bcmm)
ANTINEOPLASTIC - IMMUNOTHERAPY, T-CELL ENGAGER · MULTIPLE MYELOMA
U.S. PHARMACEUT
LYNOZYFIC (linvoseltamab-gcpt)
ANTINEOPLASTIC - IMMUNOTHERAPY, T-CELL ENGAGER · MULTIPLE MYELOMA
Regeneron Pharmaceuticals, Inc.
LUNSUMIO VELO (mosunetuzumab-axgb)
ANTINEOPLASTIC - IMMUNOTHERAPY, T-CELL ENGAGER · FOLLICULAR LYMPHOMA
GENENTECH
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Immunotherapy, T-cell Engager preselected. Add indication or manufacturer filters there.
Antineoplastic T-cell engager immunotherapies are engineered multispecific biologic agents designed to redirect endogenous cytotoxic T cells to destroy malignant cells.
Their primary mechanism of action involves simultaneously binding to the CD3 subunit of the T-cell receptor complex and a specific tumor-associated antigen, forming an immunological synapse that triggers targeted, MHC-independent cytolytic killing.
These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma.
-
cancer.gov
Antineoplastic T-cell engager immunotherapies are engineered multispecific biologic agents designed to redirect endogenous cytotoxic T cells to destroy malignant cells
-
nih.gov
Antineoplastic T-cell engager immunotherapies are engineered multispecific biologic agents designed to redirect endogenous cytotoxic T cells to destroy malignant cells Their primary mechanism of action involves simultaneously binding to the CD3 subunit of the T-cell receptor complex and a specific tumor-associated antigen, forming an immunological synapse that triggers targeted, MHC-independent cytolytic killing
-
fda.gov
Their primary mechanism of action involves simultaneously binding to the CD3 subunit of the T-cell receptor complex and a specific tumor-associated antigen, forming an immunological synapse that triggers targeted, MHC-independent cytolytic killing
-
fda.gov
These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma
-
fda.gov
These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma
-
cancer.gov
These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma
-
upmc.com
These therapies are widely utilized in the treatment of hematologic malignancies, such as acute lymphoblastic leukemia, multiple myeloma, and non-Hodgkin lymphomas, as well as selected solid tumors including small cell lung cancer and uveal melanoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.